Reports
Reports
Sale
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Self Amplifying RNA Vaccines Market Overview
3.1 Global Self Amplifying RNA Vaccines Market Historical Value (2017-2023)
3.2 Global Self Amplifying RNA Vaccines Market Forecast Value (2024-2032)
4 Vendor Positioning Analysis
4.1 Key Vendors
4.2 Prospective Leaders
4.3 Niche Leaders
4.4 Disruptors
5 Global Self Amplifying RNA Vaccines Market Landscape*
5.1 Global Self Amplifying RNA Vaccines Market: Developers Landscape
5.1.1 Analysis by Year of Establishment
5.1.2 Analysis by Company Size
5.1.3 Analysis by Region
5.2 Global Self Amplifying RNA Vaccines Market: Product Landscape
5.2.1 Analysis by Route of Administration
5.2.2 Analysis by Application
6 Global Self Amplifying RNA Vaccines Market Dynamics
6.1 Market Drivers and Constraints
6.2 SWOT Analysis
6.2.1 Strengths
6.2.2 Weaknesses
6.2.3 Opportunities
6.2.4 Threats
6.3 PESTEL Analysis
6.3.1 Political
6.3.2 Economic
6.3.3 Social
6.3.4 Technological
6.3.5 Legal
6.3.6 Environment
6.4 Porter’s Five Forces Model
6.4.1 Bargaining Power of Suppliers
6.4.2 Bargaining Power of Buyers
6.4.3 Threat of New Entrants
6.4.4 Threat of Substitutes
6.4.5 Degree of Rivalry
6.5 Key Demand Indicators
6.6 Key Price Indicators
6.7 Industry Events, Initiatives, and Trends
6.8 Value Chain Analysis
7 Global Self Amplifying RNA Vaccines Market Segmentation (2017-2032)
7.1 Global Self Amplifying RNA Vaccines Market (2017-2032) by Route of Administration
7.1.1 Market Overview
7.1.2 Intradermal
7.1.3 Intranasal
7.1.4 Intramuscular
7.1.5 Others
7.2 Global Self Amplifying RNA Vaccines Market (2017-2032) by Application
7.2.1 Market Overview
7.2.2 Influenza
7.2.3 Rabies
7.2.4 HIV-1
7.2.5 COVID-19
7.2.6 Respiratory Syncytial Virus (RSV)
7.2.7 Ebola
7.2.8 Others
7.3 Global Self Amplifying RNA Vaccines Market (2017-2032) by Region
7.3.1 Market Overview
7.3.2 North America
7.3.3 Europe
7.3.4 Asia Pacific
7.3.5 Latin America
7.3.6 Middle East and Africa
8 North America Self Amplifying RNA Vaccines Market (2017-2032)
8.1 North America Self Amplifying RNA Vaccines Market (2017-2032) by Route of Administration
8.1.1 Market Overview
8.1.2 Intradermal
8.1.3 Intranasal
8.1.4 Intramuscular
8.1.5 Others
8.2 North America Self Amplifying RNA Vaccines Market (2017-2032) by Application
8.2.1 Market Overview
8.2.2 Influenza
8.2.3 Rabies
8.2.4 HIV-1
8.2.5 COVID-19
8.2.6 Respiratory Syncytial Virus (RSV)
8.2.7 Ebola
8.2.8 Others
8.3 North America Self Amplifying RNA Vaccines Market (2017-2032) by Country
8.3.1 United States of America
8.3.2 Canada
9 Europe Self Amplifying RNA Vaccines Market (2017-2032)
9.1 Europe Self Amplifying RNA Vaccines Market (2017-2032) by Route of Administration
9.1.1 Market Overview
9.1.2 Intradermal
9.1.3 Intranasal
9.1.4 Intramuscular
9.1.5 Others
9.2 Europe Self Amplifying RNA Vaccines Market (2017-2032) by Application
9.2.1 Market Overview
9.2.2 Influenza
9.2.3 Rabies
9.2.4 HIV-1
9.2.5 COVID-19
9.2.6 Respiratory Syncytial Virus (RSV)
9.2.7 Ebola
9.2.8 Others
9.3 Europe Self Amplifying RNA Vaccines Market (2017-2032) by Country
9.3.1 United Kingdom
9.3.2 Germany
9.3.3 France
9.3.4 Italy
9.3.5 Others
10 Asia Pacific Self Amplifying RNA Vaccines Market (2017-2032)
10.1 Asia Pacific Self Amplifying RNA Vaccines Market (2017-2032) by Route of Administration
10.1.1 Market Overview
10.1.2 Intradermal
10.1.3 Intranasal
10.1.4 Intramuscular
10.1.5 Others
10.2 Asia Pacific Self Amplifying RNA Vaccines Market (2017-2032) by Application
10.2.1 Market Overview
10.2.2 Influenza
10.2.3 Rabies
10.2.4 HIV-1
10.2.5 COVID-19
10.2.6 Respiratory Syncytial Virus (RSV)
10.2.7 Ebola
10.2.8 Others
10.3 Asia Pacific Self Amplifying RNA Vaccines Market (2017-2032) by Country
10.3.1 China
10.3.2 Japan
10.3.3 India
10.3.4 ASEAN
10.3.5 Australia
10.3.6 Others
11 Latin America Self Amplifying RNA Vaccines Market (2017-2032)
11.1 Latin America Self Amplifying RNA Vaccines Market (2017-2032) by Route of Administration
11.1.1 Market Overview
11.1.2 Intradermal
11.1.3 Intranasal
11.1.4 Intramuscular
11.1.5 Others
11.2 Latin America Self Amplifying RNA Vaccines Market (2017-2032) by Application
11.2.1 Market Overview
11.2.2 Influenza
11.2.3 Rabies
11.2.4 HIV-1
11.2.5 COVID-19
11.2.6 Respiratory Syncytial Virus (RSV)
11.2.7 Ebola
11.2.8 Others
11.3 Latin America Self Amplifying RNA Vaccines Market (2017-2032) by Country
11.3.1 Brazil
11.3.2 Argentina
11.3.3 Mexico
11.3.4 Others
12 Middle East and Africa Self Amplifying RNA Vaccines Market (2017-2032)
12.1 Middle East and Africa Self Amplifying RNA Vaccines Market (2017-2032) by Route of Administration
12.1.1 Market Overview
12.1.2 Intradermal
12.1.3 Intranasal
12.1.4 Intramuscular
12.1.5 Others
12.2 Middle East and Africa Self Amplifying RNA Vaccines Market (2017-2032) by Application
12.2.1 Market Overview
12.2.2 Influenza
12.2.3 Rabies
12.2.4 HIV-1
12.2.5 COVID-19
12.2.6 Respiratory Syncytial Virus (RSV)
12.2.7 Ebola
12.2.8 Others
12.3 Middle East and Africa Self Amplifying RNA Vaccines Market (2017-2032) by Country
12.3.1 Saudi Arabia
12.3.2 United Arab Emirates
12.3.3 Nigeria
12.3.4 South Africa
12.3.5 Others
13 Regulatory Framework
13.1 Regulatory Overview
13.2 US FDA
13.3 EU EMA
13.4 INDIA CDSCO
13.5 JAPAN PMDA
13.6 Others
14 Patent Analysis
14.1 Analysis by Type of Patent
14.2 Analysis by Publication Year
14.3 Analysis by Issuing Authority
14.4 Analysis by Patent Age
14.5 Analysis by CPC Analysis
14.6 Analysis by Patent Valuation
14.7 Analysis by Key Players
15 Clinical Trial Analysis
15.1 Analysis by Trial Registration Year
15.2 Analysis by Trial Status
15.3 Analysis by Trial Phase
15.4 Analysis by Therapeutic Area
15.5 Analysis by Geography
16 Grants Analysis
16.1 Analysis by Year
16.2 Analysis by Amount Awarded
16.3 Analysis by Issuing Authority
16.4 Analysis by Grant Application
16.5 Analysis by Funding Institute
16.6 Analysis by NIH Departments
16.7 Analysis by Recipient Organization
17 Funding and Investment Analysis
17.1 Analysis by Funding Instances
17.2 Analysis by Type of Funding
17.3 Analysis by Funding Amount
17.4 Analysis by Leading Players
17.5 Analysis by Leading Investors
17.6 Analysis by Geography
18 Strategic Initiatives
18.1 Analysis by Partnership Instances
18.2 Analysis by Type of Partnership and Collaborations
18.3 Analysis by Joint Ventures
18.4 Analysis by Leading Players
18.5 Analysis by Geography
19 Supplier Landscape
19.1 Market Share Analysis, By Region (Top 5 Companies)
19.1.1 Market Share Analysis: Global
19.1.2 Market Share Analysis: North America
19.1.3 Market Share Analysis: Europe
19.1.4 Market Share Analysis: Asia Pacific
19.1.5 Market Share Analysis: Others
19.2 Gennova Biopharmaceuticals Limited
19.2.1 Financial Analysis
19.2.2 Product Portfolio
19.2.3 Demographic Reach and Achievements
19.2.4 Company News and Development
19.2.5 Certifications
19.3 Arcturus Therapeutics, Inc.
19.3.1 Financial Analysis
19.3.2 Product Portfolio
19.3.3 Demographic Reach and Achievements
19.3.4 Company News and Development
19.3.5 Certifications
19.4 VLP Therapeutics Japan, LLC
19.4.1 Financial Analysis
19.4.2 Product Portfolio
19.4.3 Demographic Reach and Achievements
19.4.4 Company News and Development
19.4.5 Certifications
19.5 CSL Limited
19.5.1 Financial Analysis
19.5.2 Product Portfolio
19.5.3 Demographic Reach and Achievements
19.5.4 Company News and Development
19.5.5 Certifications
19.6 TriLink BioTechnologies
19.6.1 Financial Analysis
19.6.2 Product Portfolio
19.6.3 Demographic Reach and Achievements
19.6.4 Company News and Development
19.6.5 Certifications
19.7 ImmunityBio, Inc.
19.7.1 Financial Analysis
19.7.2 Product Portfolio
19.7.3 Demographic Reach and Achievements
19.7.4 Company News and Development
19.7.5 Certifications
19.8 Pfizer Inc.
19.8.1 Financial Analysis
19.8.2 Product Portfolio
19.8.3 Demographic Reach and Achievements
19.8.4 Company News and Development
19.8.5 Certifications
19.9 Gritstone bio, Inc.
19.9.1 Financial Analysis
19.9.2 Product Portfolio
19.9.3 Demographic Reach and Achievements
19.9.4 Company News and Development
19.9.5 Certifications
19.10 eTheRNA Immunotherapies NV
19.10.1 Financial Analysis
19.10.2 Product Portfolio
19.10.3 Demographic Reach and Achievements
19.10.4 Company News and Development
19.10.5 Certifications
20 Global Self Amplifying RNA Vaccines Market – Distribution Model (Additional Insight)
20.1 Overview
20.2 Potential Distributors
20.3 Key Parameters for Distribution Partner Assessment
21 Key Opinion Leaders (KOL) Insights (Additional Insight)
*Additional insights provided are customisable as per client requirements.
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
**The supplier list is not exhaustive. Moreover, we can provide analysis of companies as per custom requests.
Datasheet
Single User License
Five User License
Corporate License
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.